Bapotulimab (BAY-1905254) is a fully human Showed significantly increased antigen-specific T-cell proliferation and cytotoxicity.
[1]. Julia Huetter, et al. Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2). Cancer Immunol Res. 2020 Jul;8(7):895-911.
















